北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Kidney Cancer Working Group Report
作者: Naito, Seiji1; Tomita, Yoshihiko2; Rha, Sun Young3; Uemura, Hirotsugu4; Oya, Mototsugu5; Song, He Zhi6; Zhong, Li Han7; Wahid, Mohamed Ibrahim Bin A.8
关键词: Renal cell carcinoma ; Asia ; Guidelines ; Racial differences
刊名: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
发表日期: 2010-09-01
DOI: 10.1093/jjco/hyq127
卷: suppl.1, 页:i51-i56
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: RENAL-CELL CARCINOMA ; JAPANESE PATIENTS ; INTERFERON-ALPHA ; PHASE-II ; SUNITINIB ; EFFICACY ; SAFETY ; SORAFENIB
英文摘要:

Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma. Globally, the incidence and mortality rates are increasing by 2-3% per decade. Kidney cancer is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer. The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. High-dose interleukin-2 (IL-2) is administered in some countries, whereas low-dose IL-2 and interferon-alpha (IFN-alpha) are popular in Japan. Molecular-targeted drugs, including sunitinib, bevacizumab and sorafenib, are being used for previously untreated and refractory patients. Asian and non-Asian populations have shown large differences in the incidences of adverse events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations. Guidelines from the National Comprehensive Cancer Network , etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity data from Asian patients are lacking. Some drugs cause adverse effects in Asians because their recommended dosages are optimal for Caucasians but may be too high for Asians. Further research is necessary to develop optimal treatment strategies for Asians.

语种: 英语
WOS记录号: WOS:000282175200008
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66674
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Yamagata Univ, Fac Med, Dept Urol, Yonezawa, Yamagata, Japan
2.Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, Fukuoka 8128582, Japan
3.Yonsei Univ, Coll Med, Yonsei Canc Ctr, Canc Metastasis Res Ctr,Div Med Oncol, Seoul, South Korea
4.Peking Univ, Hosp 1, Chinese RCC Workgrp RCC Treatment Guideline, Dongcheng, Peking, Peoples R China
5.Peking Union Hosp, Dongcheng, Peking, Peoples R China
6.Kinki Univ, Sch Med, Dept Urol, Osaka 589, Japan
7.Keio Univ, Fac Med, Dept Urol, Shinjuku Ku, Tokyo, Japan
8.Malaysian Oncol Soc, Petaling Jaya, Malaysia

Recommended Citation:
Naito, Seiji,Tomita, Yoshihiko,Rha, Sun Young,et al. Kidney Cancer Working Group Report[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY,2010,suppl.1:i51-i56.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Naito, Seiji]'s Articles
[Tomita, Yoshihiko]'s Articles
[Rha, Sun Young]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Naito, Seiji]‘s Articles
[Tomita, Yoshihiko]‘s Articles
[Rha, Sun Young]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace